Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Larry Todd Edwards Sells 3,687 Shares of Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Larry Todd Edwards sold 3,687 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $25.18, for a total value of $92,838.66. Following the completion of the sale, the insider directly owned 175,178 shares of the company’s stock, valued at approximately $4,410,982.04. This represents a 2.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Larry Todd Edwards also recently made the following trade(s):

• On Monday, February 2nd, Larry Todd Edwards sold 2,052 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $25.50, for a total transaction of $52,326.00.

Arcutis Biotherapeutics Price Performance

Shares of Arcutis Biotherapeutics stock opened at $23.60 on Wednesday. The stock has a market capitalization of $2.93 billion, a price-to-earnings ratio of -168.56 and a beta of 1.66. The company has a fifty day moving average of $27.02 and a 200-day moving average of $24.03. Arcutis Biotherapeutics, Inc. has a 52-week low of $11.86 and a 52-week high of $31.77. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.99 and a current ratio of 3.17.

Arcutis Biotherapeutics (NASDAQ:ARQT) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.10. Arcutis Biotherapeutics had a negative net margin of 4.29% and a negative return on equity of 10.26%. The business had revenue of $129.50 million during the quarter, compared to the consensus estimate of $110.79 million. Equities research analysts expect that Arcutis Biotherapeutics, Inc. will post -1.33 EPS for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on ARQT. HC Wainwright boosted their price objective on Arcutis Biotherapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Zacks Research lowered shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, December 29th. Needham & Company LLC boosted their price objective on shares of Arcutis Biotherapeutics from $31.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Wall Street Zen downgraded shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research note on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $31.86.

Arcutis Biotherapeutics News Roundup

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Pipeline update — Arcutis enrolled the first participant in a Phase 1a/1b study of ARQ‑234 (a CD200R agonist) to assess safety/tolerability in healthy volunteers and adults with moderate‑to‑severe atopic dermatitis. This is a clear development catalyst supporting longer‑term growth potential. Read More.
• Neutral Sentiment: Broker update — Mizuho trimmed its price target (reported moves show PT cut from $37 to $35) but retained an Outperform stance; that lowers near‑term upside while keeping analyst conviction intact. Read More.
• Neutral Sentiment: Fund filings — Baron Health Care Fund published Q4 activity (no clear large position change in ARQT reported), so fund flows aren’t a decisive driver based on available filings. Read More.
• Neutral Sentiment: Short‑interest reporting in the feeds is inconsistent/erroneous (reports show 0 shares / NaN changes) and provides no reliable signal; treat those numbers as unreliable until clarified by exchange data.
• Negative Sentiment: Clustered insider selling — Multiple insiders sold shares between Feb 27–Mar 2 (notable filings: Todd Watanabe ~37,349 shares; Masaru Matsuda 8,733 shares plus earlier sales; CFO Latha Vairavan; Patrick Burnett). Aggregated insider dispositions total tens of thousands of shares and are likely weighing on sentiment because clustered sales often trigger investor concern. Representative filings: Watanabe Form 4 Read More., Matsuda Form 4 Read More., MarketBeat roundup Read More.
• Negative Sentiment: Analyst downgrade / negative note — Coverage cited in the newsfeed reports a downgrade and a pessimistic near‑term forecast that corresponded with a sharp intraday drop; that broker action appears to have amplified selling pressure. Read More.

Hedge Funds Weigh In On Arcutis Biotherapeutics

Institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its position in Arcutis Biotherapeutics by 21.4% during the first quarter. AQR Capital Management LLC now owns 248,196 shares of the company’s stock valued at $3,882,000 after buying an additional 43,716 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Arcutis Biotherapeutics by 3.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,417 shares of the company’s stock worth $1,118,000 after acquiring an additional 2,063 shares in the last quarter. AlphaQuest LLC lifted its position in Arcutis Biotherapeutics by 101.1% during the 2nd quarter. AlphaQuest LLC now owns 11,921 shares of the company’s stock valued at $167,000 after acquiring an additional 5,994 shares during the period. Corton Capital Inc. bought a new stake in Arcutis Biotherapeutics during the second quarter worth about $238,000. Finally, Atlas Wealth LLC bought a new stake in Arcutis Biotherapeutics during the second quarter worth about $138,000.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.